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Abstract
Background: The components of nucleosomes, which contain DNA and histones, are released into the circulation
from damaged cells and can promote inflammation. We studied whether the on-admission levels of circulating
nucleosomes predict the development of severe acute pancreatitis (AP), in particular among the patients who
present without clinical signs of organ dysfunction.
Methods: This is a prospective study of 74 AP patients admitted to Helsinki University Hospital from 2003 to 2007.
Twenty-three patients had mild, 27 moderately severe, and 24 severe AP as defined by the revised Atlanta criteria.
14/24 severe AP patients had no sign of organ dysfunction on admission (modified marshall score <2). Blood
samples were obtained on admission and the plasma levels of nucleosomes were measured using enzyme-linked
immunosorbent assay.
Results: The on-admission levels of nucleosomes were significantly higher in severe AP than in mild or moderately
severe AP (p < 0.001 for all), higher in non-survivors (n = 8) than in survivors (p = 0.019), and correlated with the on-
admission levels of C-reactive protein (p < 0.001) and creatinine (p < 0.001). Among the AP patients who presented
without organ dysfunction, the on-admission nucleosome level was an independent predictor of severe AP (p = 0.038,
gender-adjusted forward-stepping logistic regression).
Conclusions: Circulating nucleosome levels may be helpful in identifying, on admission to hospital, the AP patients
who present without clinical signs of organ dysfunction, and, yet, are bound to develop organ dysfunction during
hospitalization.
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Background
Acute pancreatitis (AP) is usually a mild disease with
favorable outcome. However, about 20 % of the patients
develop moderately severe or severe disease, as defined by
the revised Atlanta classification [1]. Moderately severe
AP is characterized by the presence of local complications
and/or transient (<48 h) organ dysfunction (OD) and very
low mortality [2]. In severe AP, OD is persistent and mor-
tality high, up to 70 % [2–5]. Evidence has accumulated to
show that early aggressive intravenous hydration decreases
morbidity and mortality [6, 7]. In addition, the patients at
risk to develop severe AP, particularly those who present
without OD, might benefit from immunomodulatory
treatment [8–10]. About half of the AP patients with
OD do not have clinical signs of OD at presentation
[8, 11, 12]. At present, there are no means to identify
these patients on admission to the hospital.
The inflammatory reaction in AP is considered to have
its origin in premature activation of pancreatic proteases
promoting acinar cell apoptosis and necrosis. Damaged
or dying pancreatic acinar cells release intracellular con-
tents including nuclear damage-associated molecular
patterns (nDAMPs), such as DNA and histones, which
promote the accumulation of innate immune cells into
the pancreas and generation of cytokines, among other
soluble mediators of inflammation. The release of phlo-
gistic mediators into the circulation elicits systemic
inflammation, which is considered to contribute to the
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development of remote organ injury (for reviews, see
refs [13, 14]).
Nucleosome, a subunit of nuclear chromatin, consists of
a central core protein formed by an octamer of the
double-represented histone and 147 base pairs of double-
stranded DNA [15]. Cellular damage, such as apoptosis
and necrosis, promotes the release of nucleosomes,
among other nDAMPS, into the extracellular space,
where DNA and histone exhibit pro-inflammatory
activity [14, 16]. Nucleosomes can also be exported
within neutrophil extracellular traps (NETs) during
NETosis, a unique form of neutrophil cell death at sites
of infection and inflammation [17, 18]. Although
elevated levels of circulating nucleosomes are detected
in patients with sepsis [19, 20], in other disorders char-
acterized of systemic inflammation [21–23], and in
experimental AP [24], to our knowledge, nucleosome
levels have not been systematically studied in patients
with AP. This prompted us to investigate whether the
on-admission plasma nucleosome levels associate with
the severity of AP and predict the development of
severe AP, in other words persistent OD.
Methods
Patients
A cohort of 74 prospectively collected non-consecutive
patients with AP admitted to Helsinki University
Hospital between June 2003 and December 2007 were
included in the study. Exclusion criteria were previous
history of chronic pancreatitis and the onset of symp-
toms more than 72 h before admittance to the hospital.
The diagnosis of AP was made if two of the following
three features were present: acute onset of upper epigas-
tric pain, serum or plasma amylase level at least three
times greater than the upper limit of normal, and charac-
teristic findings of AP in imaging studies (computed tom-
ography or magnetic resonance imaging). The patients
were treated according to the international guidelines [25]
with, e.g., early aggressive intravenous hydration, no
routine use of prophylactic antibiotics, nasojejunal tube
for enteral feeding in severe AP, and endoscopic retro-
grade cholangiopancreatography if concurrent cholangitis
was present.
After inclusion, demographic and clinical characteristics
of patients were collected from medical charts. The sever-
ity of AP was graded retrospectively according to the
revised Atlanta classification [1] into mild (no systemic or
local complication), moderately severe (local and/or
systemic complication without persistent OD), and severe
(persistent OD). Acute physiology and chronic health
evaluation (APACHE) II score, sepsis-related organ failure
assessment (SOFA) score, and modified marshall score
(MMS) were determined to evaluate the severity of OD on
admission. MMS [26] was used for assessing the presence
of OD on admission, as recommended in the revised
Atlanta classification [1]. In MMS, three organ systems (re-
spiratory, renal, and cardiac) are assessed, and if the score is
≥2 for one of those organ systems, OD is present. The flow
chart of the patients is presented in Fig. 1.
Each patient, or next to kin, gave informed consent.
Ethics Committee of Helsinki University Hospital
(Department of Surgery) approved the study.
Samples and sample analyses
The plasma samples were taken 0–12 h after admission,
collected into EDTA-treated tubes and stored at −80 °C
until they were assayed. Nucleosomes were quantified
with Cell Death Detection ELISAPLUS (Roche, Basel,
Switzerland) according to the instructions of the manu-
facturer. The results are presented as absorbance units
(AU). Negative values were computed to zero.
Plasma levels of C-reactive protein (CRP) (normal ref-
erence range less than 10 mg/L) and creatinine (normal
reference range 50–90 μmol/L) were determined in
accordance with the hospital laboratory routine. CRP
and creatinine levels were used as reference markers be-
cause they belong to routine follow-up blood chemistry
of AP patients and have prognostic value in AP [7, 34].
The median storage time of the plasma samples was
long, in mild AP group 9.3 years (range 6.2–9.8 years),
moderately severe AP group 8.3 years (range 5.8–
9.8 years), and severe AP group 7.3 years (range 5.3–
9.8 years), (p < 0.001, Jonckheere-Terpstra test for trend).
However, the sample age did not correlate with nucleo-
some level in mild, moderately severe or severe AP (p =
0.153, p = 0.928, and p = 0.631, respectively), and in
multivariate logistic regression analysis nucleosome level
remained as an independent predictor of OD regardless
of the storage time.
Fig. 1 Flow chart of the patients. Patients’ classification according to
admission modified marshall score (MMS) and patients’ outcome
according to the revised Atlanta criteria [1]. OD organ dysfunction,
AP acute pancreatitis
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Statistics
Statistical analysis was performed using IBM SPSS® Stat-
istic version 19 (SPSS, Chicago, Illinois, USA) statistical
software. Nonparametric tests were used because of the
skewness of the data. The results are given as medians
and interquartile ranges (IQRs) or number of patients
and percentages. Comparisons between two groups were
made using the Mann-Whitney U test for continuous
variables or using Fisher’s exact test for binary variables.
Comparisons between three ordered groups were tested
with the Jonckheere-Terpstra test for trend. Correlations
between two continuous variables were done using
Spearman rank correlation. P values of less than 0.05
were considered significant, and double-sided tests were
used. Receiver operator characteristic (ROC) curve ana-
lysis was used to find a clinically optimal cutoff value for
each biomarker. In this study, we determined the specifi-
city >90 % and chose the point on the curve where the
longest increase in the sensitivity of the slope declines.
Areas under the ROC curves (AUC) were calculated, as
well as corresponding sensitivities, specificities, positive
likelihood ratios (+LR), negative likelihood ratios (−LR),
and diagnostic odds ratios (DOR) for cutoff values, with
95 % confidence intervals [27]. DOR is the ratio of the
odds of positive test result among patients with OD to
the odds of a positive test result among the patients
without OD. The higher the value, the better the
discriminatory test performance is [28]. Finally, logistic
regression analysis was performed to identify independ-
ent markers predicting severe AP. Forward conditional
stepping was used to select variables into the post hoc
model with p < 0.05 inclusion criteria. Interactions were
considered, but no significant interactions were found.
Results
Patients
Characteristics of the patients are shown in Table 1. All
patients with severe AP developed either respiratory or
renal failure needing mechanical invasive ventilation
and/or haemodialysis. Seven of them (29 %) died, four of
whom during the first hospital week (range 1–6 days),
and the other three patients 11–90 days after admission.
One patient, already recovering from moderately severe
AP, experienced sudden death of unknown immediate
cause.
On-admission nucleosome levels correlate with severity
of AP
The on-admission levels of nucleosomes increased along
with the severity of AP and were significantly higher in
patients with severe AP than in mild or moderately
Table 1 Baseline characteristics of patients
Variable Mild Moderately severe Severe
(n = 23) (n = 27) (n = 24)
Male sex, (%) 15 (65) 19 (70) 23 (96)
Age (years) 44 (37–64) 52 (44–61) 43 (37–51)
Etiology of acute pancreatitis, (%)
Alcohol 13 (57) 20 (74) 21 (88)
Biliary 6 (26) 7 (26) 1 (4)
Idiopathic or other 4 (17) 0 2 (8)
Duration of symptoms (hr) 24 (12–60) 24 (12–48) 24 (12–48)
CRP on admission (mg/L) 8 (5–17) 84 (9–231) 109 (15–292)
Creatinine on admission (μmol/L) 59 (49–68) 61 (53–101) 92 (66–243)
APACHE II 6 (1–7) 8 (5–10) 8 (6–15)
SOFA on admission 0 (0–1) 1 (1–3) 4 (1–6)
MMS on admission 0 (0–1) 1 (0–4) 1 (1–4)
MMS < 2 on admission, (%) 23 (100) 21 (78) 14 (58)
MMS≥ 2 on admission, (%) 0 6 (22) 10 (42)
Mechanical invasive ventilation, (%) 0 1 (4) 22 (92)
Haemodialysis, (%) 0 0 16 (67)
Length of hospital stay (days) 4 (3–6) 11 (9–15) 28 (17–35)
Mortality, (%) 0 1 (4) 7 (29)
All numerical data are median (interquartile range) or number (%). APACHE II was determined using the most abnormal value for each physiological variable
within 24 h of admission to the hospital
APACHE acute physiology and chronic health evaluation, CRP C-reactive protein, MMS modified marshall score, SOFA sepsis-related organ failure assessment score
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severe AP (p < 0.001) and higher in non-survivors than
in survivors (p = 0.019, Table 2).
The nucleosome level correlated with MMS (r = 0.525,
p < 0.001), APACHE II (r = 0.414, p < 0.001), and SOFA
score (r = 0.392, p = 0.001). There was also a positive
correlation between on-admission levels of nucleosomes
and CRP (r = 0.422, p < 0.001), between those of nucleo-
somes and creatinine (r = 0.423, p < 0.001), and those of
CRP and creatinine (r = 0.396, p < 0.001).
Nucleosome, CRP, and creatinine levels as predictors of
severe AP
All patients
Classification criteria, the Atlanta criteria, and their re-
vised form [1] have been commonly used also in predict-
ing the outcome of AP. We therefore first determined if
the on-admission level of circulating nucleosomes pre-
dicts the development of severe AP among all patients
categorized according to the revised Atlanta criteria [1].
The predictive value was measured by determining the
AUCs from the ROC curve (Fig. 2a). AUCs were 0.718
for nucleosomes, 0.770 for creatinine, and 0.673 for CRP
(Table 4), indicating that the predictive values of the
variables were comparable. We then chose clinically
optimal cutoff values (specificity >90 %) from the ROC
curves to analyze the corresponding statistical parame-
ters for the biomarkers to predict severe AP. Of the
three variables studied, creatinine (cutoff ≥110 μmol/L)
had the highest predictive power of OD with the sensi-
tivity of 46 %, the specificity of 91 % (Table 4).
In univariate logistic regression analysis nucleosomes,
CRP and creatinine, both as continuous and binary vari-
ables, predicted the development of severe AP. The
stepwise forward logistic regression analysis of CRP, cre-
atinine, and nucleosomes (gender adjusted) revealed that
creatinine, as a binary variable (cutoff ≥110 μmol/L), was
an independent, significant predictor of severe AP
(Table 5).
Table 2 The levels of circulating nucleosomes on admission in
relation to the severity of acute pancreatitis and among
survivors and non-survivors
Nucleosome level (AU)
Mild 0.005 (0.002–0.14)
Moderately severe 0.09 (0.03–0.32)
Severe 0.30 (0.18–0.45)
p value <0.001a
Survivors 0.09 (0.02–0.27)
Non-survivors 0.38 (0.19–0.77)
p value = 0.019b
All numerical data are median (interquartile range)
AU absorbance unit
aJonckheere-Terpstra for trend
bMann-Whitney U test
Fig. 2 Receiver-operating characteristic curves of circulating
nucleosomes, C-reactive protein (CRP) and creatinine for the prediction
of severe acute pancreatitis among a all patients (n= 74), b patients with
moderately severe or severe acute pancreatitis (n= 51), and c patients
with modified marshall score <2 on admission (n= 58). Arrows point to
clinically optimal cutoff points used to calculate the statistical parameters
of each biomarker for Table 4
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Moderately severe AP and severe AP
Because most patients with mild AP recover unevent-
fully within a few days, we excluded these patients to
reveal whether moderately severe AP (n = 27) can be
distinguished from severe AP (n = 24) using the on-
admission level of circulating nucleosomes.
AUCs were 0.661 for nucleosomes, 0.717 for creatin-
ine, and 0.550 for CRP (Table 4). We then chose the
new clinically optimal cutoff values to predict severe AP
with high specificity (>90 %) optimized for moderately se-
vere and severe AP patients from the ROC curves (Fig. 2b).
The cutoff points were ≥386 mg/L for CRP, ≥287 μmol/L
for creatinine, and ≥0.57 AU for nucleosomes. The specifi-
city and sensitivity for nucleosomes and those for creatin-
ine were comparable (Table 4).
In univariate logistic regression analysis, however, only
male gender was a significant predictor of severe AP.
Using the gender-adjusted stepwise forward logistic
regression analysis of nucleosomes and creatinine, only
male gender was an independent predictor of severe AP
(Table 5).
Predicting severe AP in patients with OD on admission (n = 16)
A question of clinical interest is whether nucleosome
levels distinguish, on admission, transient OD patients
from persistent OD patients. Six of the 16 patients who
presented with OD had transient OD, in other words,
OD resolved within 48 h, and were ultimately allocated
into the moderately severe AP group. The nucleosome,
CRP, or creatinine levels of the six transient OD patients
did not differ significantly from those of the ten persist-
ent OD patients (Table 3).
Nucleosome levels predict severe AP among patients
without OD on admission (n = 58)
A total of 14/24 patients with severe AP and another 44
patients with mild or moderately severe AP had MMS
<2 on admission (Fig. 1). Thus, we analyzed if the vari-
able studied predicted the development of OD of the 14
patients who presented without OD. The AUCs were
0.648 for nucleosome, 0.670 for creatinine, and 0.539 for
CRP (Table 4). We then determined the clinically
optimal cutoff values (specificity >90 %) using the ROC
curves of the 58 patients without OD on admission
(Fig. 2c). The new cutoff values were much alike com-
pared to the cutoff values of all the patients (Table 4).
In univariate logistic regression analysis, only nucleo-
some, as a continuous or a binary variable, was a signifi-
cant predictor of severe AP. Using the gender adjusted
stepwise forward logistic regression analysis model of
nucleosomes and creatinine, nucleosome as a continu-
ous variable served as an independent predictor of
severe AP (Table 5).
Discussion
The results show that the circulating nucleosome levels
in patients with AP are elevated, associate with the
severity of AP and predict, on admission to hospital, the
development of severe AP among the patients who
present without clinical signs of OD (MMS <2). Our
results are in accordance with the finding that circulat-
ing DNA levels are elevated in patients with severe AP
[31, 32] and that nucleosome levels are elevated in
experimental pancreatitis [24]. To our knowledge, this
study demonstrates, for the first time, the predictive
value of circulating nucleosomes in AP.
Several biomarkers have been evaluated as predictors
of the course of AP [33–37]. However, in these studies,
OD group consistently comprised all patients with OD,
in other words, the patients who have OD already at
presentation and the patients who present without OD
but are bound to develop it. Including the former may
distort the results. Accordingly, in the present study, the
analysis of all OD patients revealed that nucleosome
levels predict OD; the analysis confined to patients with
moderately severe and severe AP, excluding mild AP,
showed that nucleosome levels did not predict OD,
while only the nucleosome levels proved to predict OD
among the patients presenting without OD. To our
knowledge, nucleosomes, as demonstrated in the present
study, and the adenosine-generating ecto-5′-nucleotid-
ase/CD73 [11] and the cytokines interleukin 8, hepato-
cyte growth factor, and granulocyte-colony stimulating
factor [12], are so far the only markers that may aid to
identify the patients who present without signs of OD
but are bound to develop it during the course of AP.
In the present study, we used highly specific cutoff
values (>90 %) instead of maximizing the sum of sensi-
tivity and specificity. The former setting, resulting in low
sensitivity of the markers, is, we think, more real in the
clinical work with limited ICU capacity. With the maxi-
mized sum of sensitivity and specificity (Figs. 2a and 2c),
the sensitivity of circulating nucleosomes in predicting
OD would have reached 83 % in the whole patient popu-
lation (specificity 72 %) and 71 % among the patients
without OD on admission (specificity 79.5 %).
Table 3 Admission levels of circulating nucleosomes, C-reactive
protein, and creatinine of the patients who presented with
organ dysfunction (MMS ≥ 2)
Variable Transient OD
(n = 6)
Persistent OD
(n = 10)
p valuea
Nucleosomes (AU) 0.41 (0.18–0.71) 0.39 (0.24–0.75) 0.635
CRP (mg/L) 234 (79–325) 297 (222–340) 0.562
Creatinine (μmol/L) 163 (60–291) 269 (156-390) 0.118
All numerical data are median (interquartile range)
AU absorbance unit, CRP C-reactive protein, MMS modified marshall score,
OD organ dysfunction
aMann-Whitney U test
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The analysis of moderately severe AP and severe AP
patients was performed, because mild AP patients may
distort the results in the whole patient population, since
they form the majority of AP patients and most of them
recover uneventfully [11]. When the patients with mild
AP were excluded from the analysis, we could not iden-
tify the patients with severe AP from those with moder-
ately severe AP with any of the markers analyzed. In the
analysis of patients who presented with OD (admission
MMS ≥2), we tried to reveal if it was possible to predict
the persistence of OD already on admission using circu-
lating nucleosome, CRP, or creatinine levels. However,
no difference between transient or persistent OD group
was found (Table 3).
The finding may be explained, at least in part, by the
origins of circulating nucleosomes in AP, which are not
known in detail but are likely to be diverse. Neutrophils
are an intriguing possibility as they are the most abun-
dant leukocytes, are activated in patients with severe AP
[38], and upon stimulation with cytokines, make extra-
cellular traps [17] comprising DNA and core histone.
Other sources of nucleosomes at least in experimental
AP include apoptosis and necroptosis [39, 40] and tissue
injury associated with circulatory shock/hypoperfusion
[41]. As to the clinical point of view, it is impossible to
say if the quickly, within 48 h, resolving OD is due to
intensive treatment or represents the natural course of
AP. Therefore, if the patient presents with OD, optimal
treatment of severe AP needs to be started immediately,
preferably in the ICU [29, 30].
The possibility that impaired renal function would
contribute significantly to the increased nucleosome
levels is not evident because nucleosome clearance ap-
pears to be mediated mostly by the liver [42–44]. In the
present study, the major finding was that nucleosome
levels predict the development of OD among the 14
patients who presented without OD. Creatinine levels of
the patients were ≤170 μmol/L, as defined by MMS
criteria [1]. Consequently, the predictive value of nucleo-
somes may not be explained by impaired renal function.
Identifying the patients who present without OD
(MMS < 2) but are bound to develop severe AP is a great
clinical challenge. Indeed, such patients form about half
of the AP patients with OD [8, 11, 12]. The findings in
the present study suggest that the on-admission levels of
circulating nucleosomes aid to identify, on admission to
hospital, the patients who present without OD but are
bound to develop it. Among such patients, the levels of
creatinine or CRP did not predict the development of
severe AP in the present study or our previous studies
Table 4 Performance of circulating nucleosomes, C-reactive protein, and creatinine in predicting severe acute pancreatitis
Cutoff AUC Sensitivity Specificity +LR −LR DOR
All patients (n = 74)
Nucleosomes ≥0.57 AU 0.718 0.21 0.96 5.2 0.83 6.3
(0.578–0.858) (0.09–0.40) (0.87–0.99) (1.1–24.9) (0.67–1.02) (1.1–35.4)
CRP ≥264 mg/L 0.673 0.33 0.91 3.8 0.73 5.2
(0.583–0.807) (0.18–0.53) (0.81–0.96) (1.4–10.4) (0.55–0.98) (1.5–18.1)
Creatinine ≥110 μmol/L 0.770 0.46 0.91 5.2 0.59 8.8
(0.654–0.886) (0.28–0.65) (0.81–0.96) (2.0–13.4) (0.41–0.87) (2.6–29.8)
Moderately severe and severe AP patients (n = 51)
Nucleosomes ≥0.57 AU 0.661 0.21 0.95 2.8 0.86 3.3
(0.502–0.821) (0.09–0.40) (0.77–0.98) (0.6–13.2) (0.68–1.08) (0.6–18.8)
CRP ≥386 mg/L 0.550 0.08 0.96 2.3 0.95 2.4
(0.390–0.710) (0.02–0.26) (0.82–0.99) (0.2–23.3) (0.83–1.10) (0.2–27.9)
Creatinine ≥287 μmol/L 0.717 0.21 0.96 5.6 0.82 6.8
(0.576–0.858) (0.09–0.41) (0.82–0.99) (0.71–44.8) (0.66–1.02) (0.7–63.4)
Patients with modified marshall score <2 on admission (n = 58)
Nucleosomes ≥0.39 AU 0.648 0.29 0.93 4.2 0.77 5.5
(0.443–0.852) (0.12–0.55) (0.82–0.98) (1.1–16.5) (0.55–1.08) (1.1–28.4)
CRP ≥227 mg/L 0.539 0.14 0.92 1.8 0.93 2.0
(0.362–0.716) (0.04–0.40) (0.82–0.97) (0.37–8.9) (0.74–1.17) (0.3–12.0)
Creatinine ≥139 μmol/L 0.670 0.14 0.98 7.3 0.87 8.3
(0.512–0.829) (0.04–0.40) (0.90–1.0) (0.7–74.6) (0.70–1.09) (0.7–99.7)
95 % confidence intervals are given in parentheses
AU absorbance unit, AUC area under the curve, CRP C-reactive protein, DOR diagnostic odds ratio, LR likelihood ratio
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[11, 12]. The present study, however, has limitations.
The number of OD patients studied was limited, and the
cutoff values were optimized. In addition, the storage
time of the plasma samples was up to 10 years. Long-
term stability investigations have revealed a 7 % decrease
per year in serum levels of nucleosomes during sample
storage at −70° [45]. However, the differences in the
sample storage time may not explain our findings because
the storage time did not correlate with nucleosome levels,
and, furthermore, nucleosome level was an independent
predictor of OD regardless of the sample age.
The release of DAMPs is considered to play central
role in the pathogenesis of AP linking local tissue dam-
age and death to systemic inflammatory response.
Therefore, DAMPs might offer several novel therapeutic
strategies in AP, such as preventing DAMP release [14],
neutralizing or blocking DAMPs [46], or blocking the
DAMP receptors or their signaling [47, 48]. The novel
therapeutic modalities may be beneficial for the AP
patients who present with OD, and, in particular, for the
patients who present without OD but are bound to
develop it.
Conclusions
Our results show that the on-admission levels of circu-
lating nucleosomes are elevated in AP and associated
with the severity of the disease. In addition, our data
show, for the first time, that nucleosome levels may
serve as an independent predictor of severe AP among
the patients who present without signs of OD (MMS < 2),
the patient group which may be an optimal target for
immunomodulatory treatment modalities.
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Table 5 Univariate and multivariate analysis of circulating
nucleosomes, C-reactive protein, and creatinine in predicting
severe acute pancreatitis
OR 95 % CI p value
All patients (n = 74)
Univariate analysis
Age (year) 0.981 0.948–1.015 0.273
Male gender 10.824 1.341–87.370 0.025
Nucleosomes (AU) 15.086 1.785–127.501 0.0127
CRP (mg/L) 1.004 1.000–1.008 0.045
Creatinine (μmol/L) 1.010 1.003–1.017 0.005
Nucleosomes ≥0.57 AU 6.316 1.127–35.402 0.036
CRP ≥264 mg/L 4.500 1.283–15.778 0.019
Creatinine ≥110 μmol/L 7.615 2.239–25.900 0.001
Multivariate analysis
Male gender 8.204 0.968–69.511 0.054
Creatinine ≥110 μmol/L 6.180 1.742–21.925 0.005
Patients with moderately severe or severe acute pancreatitis (n = 51)
Univariate analysis
Age (year) 0.974 0.936–1.014 0.207
Male gender 9.684 1.110–84.465 0.040
Nucleosomes (AU) 5.602 0.739–42.474 0.095
CRP (mg/L) 1.001 0.997–1.005 0.579
Creatinine (μmol/L) 1.007 1.000–1.013 0.052
Nucleosomes ≥0.57 AU 3.289 0.575–18.834 0.181
CRP ≥386 mg/L 2.364 0.201–27.852 0.494
Creatinine ≥287 μmol/L 6.842 0.738–63.442 0.091
Multivariate analysis
Male gender 9.684 1.110–84.465 0.040
Patients with modified marshall score <2 on admission (n = 58)
Univariate analysis
Age (year) 0.976 0.936–1.017 0.252
Male gender 6.724 0.801–56.432 0.079
Nucleosomes (AU) 33.070 1.216–899.485 0.038
CRP (mg/L) 1.000 0.993–1.006 0.883
Creatinine (μmol/L) 1.017 0.998–1.036 0.088
Nucleosomes ≥0.39 AU 5.467 1.051–28.432 0.043
CRP≥ 227 mg/L 1.667 0.271–10.244 0.581
Creatinine ≥139 μmol/L 7.167 0.598–85.946 0.120
Multivariate analysis
Male gender 6.048 0.693–52.799 0.104
Nucleosomes (AU) 33.070 1.216–899.485 0.038
AU absorbance unit, CRP C-reactive protein, OR odds ratio
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